Galera Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Galera Therapeutics, Inc. | GRTX - NASDAQ |
$14.00-$16.00 | $12.00 | $12.50 | 5 million | 11/7/2019 |
| BofA Merrill Lynch, Citigroup, Credit Suisse | ||||||
Co-Manager(s): BTIG | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-10-11 Terms Added 2019-10-28 | ||||||
Galera Therapeutics, Inc. Quote & Chart - Click for current quote - GRTX
IPO Boutique aggregates information on public companies and private companies, such as "GRTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Galera Therapeutics, Inc. (adapted from Galera Therapeutics, Inc. prospectus):
They are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "GRTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.